▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent Articles by Taylor Carmichael

Here_s_What_Investors_Should_Know_About_Cassava_s_Alzheimer_s_Drug_Candidate

Aug 11, 2021 by Taylor Carmichael and Olivia Zitkus

Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate

Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function.

What_Does_the_Future_Look_Like_for_Illumina_Stock

Aug 11, 2021 by Taylor Carmichael

What Does the Future Look Like for Illumina Stock?

The leader in the genomics space is being treated like a monopoly, and is now running into federal regulation and oversight.

Young person works on a laptop with a pencil and notepad in hand.

Aug 10, 2021 by Taylor Carmichael

This Stock Is Radically Transforming a Multitrillion-Dollar Industry

As the restaurant industry evolves into "ghost kitchens" and more people order food online, one tiny company is leading the way.

GettyImages-1298875724

Aug 9, 2021 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Vaccine Stocks for the Next Decade

Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?

Why_Does_Illumina_Want_to_Reunite_With_Grail

Aug 8, 2021 by Taylor Carmichael

Why Does Illumina Want to Reunite With Grail?

The genomics leader might be hitting a ceiling in its original business.

GettyImages-1296010642

Aug 3, 2021 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 COVID Stocks That Could Soar Higher

Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.

Phantom of the Abyss

Jul 24, 2021 by Taylor Carmichael

The Future of Gaming

Video games are undergoing a massive shift from pay-to-play to free games. But what's even more amazing is the future -- in some free games you will accumulate digital assets that increase in value.

GettyImages-1269501073

Jul 24, 2021 by Taylor Carmichael

Better Healthcare Stock: Teladoc vs. Doximity

Teladoc Health was the first mover, but it's no longer top dog by some standards.

GettyImages-108224060

Jul 20, 2021 by Taylor Carmichael

Here's Why Cassava Sciences Is Up 1,152% in the First Half of 2021

This small-cap biotech has shot up in value as the company's Alzheimer's drug makes it way through clinical trials.

GettyImages-497628994

Jul 20, 2021 by Taylor Carmichael

Why Is Cassava Sciences Stock Soaring in 2021?

The stock market is excited by the clinical trial results for its Alzheimer's drug.

GettyImages-200398520-001

Jul 19, 2021 by Taylor Carmichael

Why Schwab Stock Ran Up 37% in the First Half of 2021

Schwab's stock has doubled over the last 12 months. What's going on?

GettyImages-1268513319

Jul 14, 2021 by Taylor Carmichael

2 Cheap Stocks That Are Doubling Revenues

The market is giving tiny multiples to Carvana and eXp World. This mispricing is an opportunity for savvy investors.

GettyImages-1189508174

Jul 8, 2021 by Taylor Carmichael

2 Top Small-Cap Stocks to Buy in July

OptimizeRx and Nano-X Imaging are two of my favorite small-caps right now. Here's why.

GettyImages-483545369

Jul 3, 2021 by Taylor Carmichael

The 1 Stock I'd Buy Right Now

I'm confident that Schrodinger will be a 10-bagger over the next decade. And it might go up a lot more than that.

GettyImages-1023297106

Jun 30, 2021 by Taylor Carmichael

This Risky Micro-Cap Could Pay Off Big

Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.

My_Favorite_Biotech_Stock_Right_Now

Jun 27, 2021 by Taylor Carmichael

My Favorite Biotech Stock Right Now

I'm an owner of Schrodinger because this company's software is revolutionizing drug discovery, and it's going to be a monster stock over the next decade.

How_Amazon_Might_Win_in_Telehealth

Jun 27, 2021 by Taylor Carmichael

How Amazon Might Win in Telehealth

Amazon has a trick up its sleeve that might allow it to jump ahead of Teladoc Health.

Why_Is_Clover_Health_a_Meme_Stock_Now

Jun 27, 2021 by Taylor Carmichael

Why Is Clover Health a Meme Stock Now?

WallStreetBets is trying to start another short squeeze.

The_Upside_for_Biogen_Is_Absolutely_Wild

Jun 26, 2021 by Taylor Carmichael

The Upside for Biogen Is Absolutely Wild

It's hard to believe how large Biogen's market opportunity is, now that the FDA has approved its Alzheimer's drug.

Why_Biogen_s_FDA_Approval_Is_Shocking

Jun 26, 2021 by Taylor Carmichael

Why Biogen's FDA Approval Is Shocking

Many doctors don't like the drug, and the trial data was underwhelming. Nonetheless, Biogen's Alzheimer's drug was approved-- and the market opportunity is huge.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services